Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 3 12Phase NA 8Phase 1/2 8Phase 4 6Phase 2/3 5Phase 1 3

Status

Unknown 5Completed 3Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 4Leukemia, Monocytic, Acute 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Sorafenib × Clear all
NCT04560894 2024-02-01

HCC

Sinocelltech Ltd.

Phase 2/3 Unknown
405 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05313958 2023-07-27

SCCLG-M5

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2/3 Unknown
43 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute

NCT02794337 2022-04-27

TACE-SBRT

Tata Memorial Hospital

Phase 2/3 Unknown
67 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2/3 Unknown
595 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01747642 2012-12-12

Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

Clinical Research Organization, Dhaka, Bangladesh

Phase 2/3 Unknown
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡